Display options
Cite
Jin-Jiang H, Jin-Chun L, Min L, et al. The Design and Construction of K11: A Novel α-Helical Antimicrobial Peptide. Int J Microbiol. 2012;2012:764834doi: 10.1155/2012/764834.
Jin-Jiang, H., Jin-Chun, L., Min, L., Qing-Shan, H., & Guo-Dong, L. (2012). The Design and Construction of K11: A Novel α-Helical Antimicrobial Peptide. International journal of microbiology, 2012764834. https://doi.org/10.1155/2012/764834
Jin-Jiang, Huang, et al. "The Design and Construction of K11: A Novel α-Helical Antimicrobial Peptide." International journal of microbiology vol. 2012 (2012): 764834. doi: https://doi.org/10.1155/2012/764834
Jin-Jiang H, Jin-Chun L, Min L, Qing-Shan H, Guo-Dong L. The Design and Construction of K11: A Novel α-Helical Antimicrobial Peptide. Int J Microbiol. 2012;2012:764834. doi: 10.1155/2012/764834. Epub 2012 Feb 16. PMID: 22518150; PMCID: PMC3299254.
Copy Download .nbib Format: NLM
Share it on

Int J Microbiol. 2012;2012:764834. doi: 10.1155/2012/764834. Epub 2012 Feb 16.

The Design and Construction of K11: A Novel α-Helical Antimicrobial Peptide.

International journal of microbiology

Huang Jin-Jiang, Lu Jin-Chun, Lu Min, Huang Qing-Shan, Li Guo-Dong

Affiliations

  1. State Key Laboratory of Genetic Engineering, Institute of Genetics, College of Life Science, Fudan University, Shanghai 200433, China.

PMID: 22518150 PMCID: PMC3299254 DOI: 10.1155/2012/764834

Abstract

Amphipathic α-helical antimicrobial peptides comprise a class of broad-spectrum agents that are used against pathogens. We designed a series of antimicrobial peptides, CP-P (KWKSFIKKLTSKFLHLAKKF) and its derivatives, and determined their minimum inhibitory concentrations (MICs) against Pseudomonas aeruginosa, their minimum hemolytic concentrations (MHCs) for human erythrocytes, and the Therapeutic Index (MHC/MIC ratio). We selected the derivative peptide K11, which had the highest therapeutic index (320) among the tested peptides, to determine the MICs against Gram-positive and Gram-negative bacteria and 22 clinical isolates including Acinetobacter baumannii, methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis, and Klebsiella pneumonia. K11 exhibited low MICs (less than 10 μg/mL) and broad-spectrum antimicrobial activity, especially against clinically isolated drug-resistant pathogens. Therefore, these results indicate that K11 is a promising candidate antimicrobial peptide for further studies.

References

  1. Infect Immun. 1999 Apr;67(4):2005-9 - PubMed
  2. Curr Opin Pharmacol. 2006 Oct;6(5):468-72 - PubMed
  3. J Biol Chem. 2005 Apr 1;280(13):12316-29 - PubMed
  4. J Pept Res. 2001 Dec;58(6):504-14 - PubMed
  5. Expert Rev Anti Infect Ther. 2008 Aug;6(4):453-62 - PubMed
  6. Antimicrob Agents Chemother. 2007 Apr;51(4):1398-406 - PubMed
  7. J Pept Res. 1997 Oct;50(4):279-85 - PubMed
  8. Nature. 2002 Jan 24;415(6870):389-95 - PubMed
  9. Biopolymers. 2008;90(3):369-83 - PubMed
  10. Bioinformatics. 2008 Sep 15;24(18):2101-2 - PubMed
  11. Curr Opin Immunol. 1998 Feb;10(1):41-4 - PubMed
  12. J Antimicrob Chemother. 2008 Feb;61(2):341-52 - PubMed
  13. Antimicrob Agents Chemother. 2008 Dec;52(12):4463-5 - PubMed
  14. FEBS Lett. 1998 Oct 23;437(3):258-62 - PubMed
  15. Pept Res. 1991 Jan-Feb;4(1):19-25 - PubMed
  16. Chem Biol Drug Des. 2011 Apr;77(4):225-40 - PubMed
  17. Eur J Biochem. 2001 Nov;268(21):5589-600 - PubMed
  18. Comput Biol Med. 2001 Jul;31(4):259-67 - PubMed
  19. Genome Res. 2002 Oct;12(10):1611-8 - PubMed

Publication Types